Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 101–200 of 1,000
Gasparini, S. J., Llonch, S., Borsch, O., & Ader, M. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.001 · Cited by 186
Michalakis, S., Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M. D., Becirovic, E., Bai, L., Huber, G., Beck, S. C., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.149 · Cited by 185
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
“ERGs, however, may be clearly detectable with the use of bright stimuli, consistent with an insensitive system.(28,29,34) Histopathology early on shows changes limited to the RPE, with accumulation of cytoplasmic lipid droplets that increase in size along with age of the dog.”
BackgroundSelf-citationAdeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“The work conducted by Bennett et al. has documented long-term, sustained (>7.5 years, with ongoing observation) restoration of visual function in a canine model of LCA2 after a single subretinal injection of rAAV2-RPE65 (Acland et al., 2001, 2005; Bennicelli et al., 2008).”
BackgroundInfluentialVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“immunochemistry and behavioural testing (Acland et al., 2001).”
BackgroundMolday, R. S., Zhong, M., & Quazi, F. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.02.004 · Cited by 182
Genetic medicines: treatment strategies for hereditary disorders
O'Connor, T. P., & Crystal, R. G. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1829 · Cited by 180
Persistent remodeling and neurodegeneration in late-stage retinal degeneration
Pfeiffer, R. L., Marc, R. E., & Jones, B. W. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.004 · Cited by 178
Key enzymes of the retinoid (visual) cycle in vertebrate retina
Kiser, P. D., Golczak, M., Maeda, A., & Palczewski, K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.03.005 · Cited by 177
“Initial gene therapy studies employing subretinal administration of RPE65-encoding adeno-associated virus (AAV) vectors were conducted in the Briard dog model of LCA2 and resulted in substantial visual function improvement in these animals [165].”
Personalized Diagnosis and Management of Congenital Cataract by Next-Generation Sequencing
Gillespie, R. L., O’Sullivan, J., Ashworth, J., Bhaskar, S., Williams, S., Biswas, S., Kehdi, E., Ramsden, S. C., Clayton-Smith, J., Black, G. C., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.06.006 · Cited by 178
Review and update: Current treatment trends for patients with retinitis pigmentosa
Shintani, K., Shechtman, D. L., & Gurwood, A. S. (2009) · Optometry - Journal of the American Optometric Association · doi:10.1016/j.optm.2008.01.026 · Cited by 175
Adenovirus and Adeno-Associated Virus Vectors
Lai, C. M., Lai, Y. K. Y., & Rakoczy, P. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053855 · Cited by 175
Remodeling of the Human Retina in Choroideremia: Rab Escort Protein 1 (REP-1) Mutations
Jacobson, S. G., Cideciyan, A. V., Sumaroka, A., Aleman, T. S., Schwartz, S. B., Windsor, E. A. M., Roman, A. J., Stone, E. M., & MacDonald, I. M. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0424 · Cited by 174
Self-citationCarvalho, L. S., Xu, J., Pearson, R. A., Smith, A. J., Bainbridge, J. W., Morris, L. M., Fliesler, S. J., Ding, X.-Q., & Ali, R. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr218 · Cited by 173
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
“This stimulated the interest of the more clinically-minded scientists; and, as such, translation to the clinic became imaginable (Acland et al., 2001, 2005; Cideciyan, 2010).”
Self-citationViral Strategies for Targeting the Central and Peripheral Nervous Systems
Bedbrook, C. N., Deverman, B. E., & Gradinaru, V. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-062048 · Cited by 168
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodSelf-citationRoman, A. J., Schwartz, S. B., Aleman, T. S., Cideciyan, A. V., Chico, J. D., Windsor, E. A. M., Gardner, L. M., Ying, G.-S., Smilko, E. E., Maguire, M. G., et al. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2004.09.008 · Cited by 164
“The full-field test of dark-adapted thresholds, as performed in Experiment 2, was born of the necessity to quantify vision in patients with severe retinal degenerations and unstable fixation, based on promising therapeutic directions (de Juan et al., 1999; Acland et al., 2001; Humayun et al., 2003).”
BackgroundSelf-citationSuh, S., Choi, E. H., Leinonen, H., Foik, A. T., Newby, G. A., Yeh, W.-H., Dong, Z., Kiser, P. D., Lyon, D. C., Liu, D. R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00632-6 · Cited by 163
Kijas, J. W., Cideciyan, A. V., Aleman, T. S., Pianta, M. J., Pearce-Kelling, S. E., Miller, B. J., Jacobson, S. G., Aguirre, G. D., & Acland, G. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082714499 · Cited by 164
Self-citationBaculoviral IAP Repeat-Containing-4 Protects Optic Nerve Axons in a Rat Glaucoma Model
McKinnon, S. J., Lehman, D. M., Tahzib, N. G., Ransom, N. L., Reitsamer, H. A., Liston, P., LaCasse, E., Li, Q., Korneluk, R. G., & Hauswirth, W. W. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0608 · Cited by 163
Self-citationRPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Ophthalmic Genetics · doi:10.1080/13816810802626399 · Cited by 162
Generation and characterization of chimeric recombinant AAV vectors
Hauck, B., Chen, L., & Xiao, W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00012-1 · Cited by 160
“A variety of transgenes using AAV vectors have been tested in brain, liver, muscle, and other tissues and positive results have been published [10-14].”
BackgroundGene Therapy Progress and Prospects: Recombinant adeno-associated virus (rAAV) vectors
Flotte, T. R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302233 · Cited by 158
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“In 2001, it was shown that subretinal delivery of an AAV-2 vector expressing functional RPE65 halted retinal regeneration and restored vision in these animals (Acland et al. 2001; Narfstrom et al. 2003a).”
BackgroundSiqueira, R. C., Messias, A. M. V., Voltarelli, J. C., Scott, I. U., & Jorge, R. (2011) · Retina · doi:10.1097/iae.0b013e3181f9c242 · Cited by 154
“Moreover, encouraging advances in gene therapy have led to partial reversal of the phenotypic changes observed in some animal models of RP, such as the rd mouse,(10) the rhodopsin gene–mutated mouse,(11) and the Royal College of Surgeons rat,(12,13) and in models with mutations of RPE65.(8,14,15) However, specific gen…”
BackgroundLarge animal models and gene therapy
Casal, M. L., & Haskins, M. E. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201535 · Cited by 164
OPA1-associated disorders: Phenotypes and pathophysiology
Amati‐Bonneau, P., Miléa, D., Bonneau, D., Chevrollier, A., Ferré, M., Guillet, V., Guéguen, N., Loiseau, D., de Crescenzo, M. P., Verny, C., et al. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.04.012 · Cited by 167
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
“…injection of an adeno-associated virus serotype 2 (AAV2) vector delivering the canine wild-type RPE65 cDNA resulted in rapid development of visual function, which was sustained over many years and more than a decade in a dog followed the longest (Acland et al. 2001, 2005; Cideciyan et al. 2013).”
BackgroundSelf-citationGene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149
Bramall, A. N., Wright, A. F., Jacobson, S. G., & McInnes, R. R. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153227 · Cited by 149
Self-citationAnimal models in research on retinal degenerations: past progress and future hope
Chader, G. J. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00212-7 · Cited by 147
Jacobson, S. G., Boye, S. L., Aleman, T. S., Conlon, T. J., Zeiss, C. J., Roman, A. J., Cideciyan, A. V., Schwartz, S. B., Komaromy, A. M., Doobrajh, M., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.845 · Cited by 147
Self-citationVersatility of AAV vectors for retinal gene transfer
Surace, E. M., & Auricchio, A. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.027 · Cited by 162
“, 2003), LCA due to an RPE65 gene deficiency (Acland et al., 2005; Acland et al., 2001; Dejneka et al., 2004; Jacobson et al., 2006; LeMeur et al., 2007; Narfstrom et al., 2003; Pang et al., 2006) and Ocular Albinism due to OA1 deficiency (Surace et al.”
Kim, S. R., Fishkin, N., Kong, J., Nakanishi, K., Allikmets, R., & Sparrow, J. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403499101 · Cited by 146
Simonelli, F., Ziviello, C., Testa, F., Rossi, S., Fazzi, E., Bianchi, P. E., Fossarello, M., Signorini, S., Bertone, C., Galantuomo, S., et al. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0068 · Cited by 144
Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1883 · Cited by 143
The Cis-regulatory Logic of the Mammalian Photoreceptor Transcriptional Network
Hsiau, T. H.-C., Diaconu, C., Myers, C. A., Lee, J., Cepko, C. L., & Corbo, J. C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000643 · Cited by 142
“Given recent progress in using viral vectors for intraretinal gene therapy in animal models of blindness [46,47], these novel CREs could prove useful as gene-specific drivers for rescue constructs in human gene therapy.”
BackgroundSahel, J.-A., & Roska, B. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170304 · Cited by 140
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
Self-citationAAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa
Smith, A. J., Schlichtenbrede, F. C., Tschernutter, M., Bainbridge, J. W., Thrasher, A. J., & Ali, R. R. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00144-8 · Cited by 140
Khani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 139
Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138
The human visual cortex responds to gene therapy–mediated recovery of retinal function
Ashtari, M., Cyckowski, L. L., Monroe, J. F., Marshall, K. A., Chung, D. C., Auricchio, A., Simonelli, F., Leroy, B. P., Maguire, A. M., Shindler, K. S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57377 · Cited by 138
Self-citationStarkey, M. P., Scase, T. J., Mellersh, C. S., & Murphy, S. (2005) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/4.2.112 · Cited by 162
“gene therapy experiments that target the gene products that are specifically affected in some of these dog breeds.(109,110) This highlights one of the distinct advantages of working with dogs, rather than transgenic rodents.”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_005 · Cited by 159
Batten, M. L., Imanishi, Y., Tu, D. C., Doan, T., Zhu, L., Pang, J., Glushakova, L., Moise, A. R., Baehr, W., Van Gelder, R. N., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020333 · Cited by 134
“A recombinant adenoassociated virus (rAAV) carrying wild-type (WT) Rpe65 (rAAV-Rpe65) restored visual function in this model of childhood blindness [9].”
InfluentialSelf-citationImmune response following intraocular delivery of recombinant viral vectors
Bennett, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302030 · Cited by 111
Self-citationSchlichtenbrede, F. C., MacNeil, A., Bainbridge, J. W., Tschernutter, M., Thrasher, A. J., Smith, A. J., & Ali, R. R. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301929 · Cited by 132
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Lorenz, B., Wabbels, B., Wegscheider, E., Hamel, C. P., Drexler, W., & Preising, M. N. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.01.033 · Cited by 172
In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye
Peynshaert, K., Devoldere, J., Smedt, S. C. D., & Remaut, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.007 · Cited by 143
Non-syndromic retinal ciliopathies: translating gene discovery into therapy
Estrada-Cuzcano, A., Roepman, R., Cremers, F. P. M., den Hollander, A. I., & Mans, D. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds298 · Cited by 128
Tschernutter, M., Schlichtenbrede, F. C., Howe, S. J., Balaggan, K. S., Munro, P., Bainbridge, J. W., Thrasher, A. J., Smith, A. J., & Ali, R. R. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302460 · Cited by 140
Rod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling
Léveillard, T., & Sahel, J.-A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000866 · Cited by 127
Pawlyk, B. S., Smith, A. J., Buch, P. K., Adamian, M., Hong, D.-H., Sandberg, M. A., Ali, R. R., & Li, T. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0371 · Cited by 126
“In general, it appears that RPE defects are easier to treat than photoreceptor defects and preclinical studies of gene therapy for LCA due to mutations in the RPE-specific gene RPE65 have been particularly successful.(9,11) Trials of gene therapy to treat this defect are likely to be the first to enter the clinic.”
New insights into retinoid metabolism and cycling within the retina
Tang, P. H., Kono, M., Koutalos, Y., Ablonczy, Z., & Crouch, R. K. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.002 · Cited by 122
“Gene therapy studies on mouse (Pang et al., 2006) and canine (Acland et al., 2001, 2005) models, as well as LCA2 patients (Bainbridge et al., 2008; Maguire et al., 2008, 2009), have shown that inserting a functional gene for RPE65 into RPE cells holds great promise for restoring visual function.”
Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions
Koenekoop, R. K., Lopez, I., Den Hollander, A. I., Allikmets, R., & Cremers, F. P. (2007) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2007.01534.x · Cited by 125
“Replacement of a RPE gene that encodes a retinoid cycle enzyme (RPE65) To determine whether gene replacement would work in a larger animal model, Acland et al.3 studied the effects of RPE65 replacement in the Briard dog.”
BackgroundSeeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
“This was confirmed when subretinal delivery of an AAV2 vector encoding for RPE65 was found to restore vision in the large dog model of LCA2 [24].”
BackgroundSun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedRetinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Nguyen, X., Moekotte, L., Plomp, A. S., Bergen, A. A. B., van Genderen, M. M., & Boon, C. J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087481 · Cited by 150
Beltran, W. A., Hammond, P., Acland, G. M., & Aguirre, G. D. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0845 · Cited by 124
Self-citationDefining the Residual Vision in Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Windsor, E. A. M., Schwartz, S. B., Heon, E., & Stone, E. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2696 · Cited by 121
Self-citationUnravelling the genetics of inherited retinal dystrophies: Past, present and future
Broadgate, S., Yu, J., Downes, S. M., & Halford, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.003 · Cited by 136
An Intrinsic Neural Oscillator in the Degenerating Mouse Retina
Borowska, J., Trenholm, S., & Awatramani, G. B. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5800-10.2011 · Cited by 121
“, 2006), gene therapy (Acland et al., 2001), and electronic (Weiland et al.”
BackgroundMethodClinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
“Acland et al. (2001) first demonstrated subretinal administration of RPE65 cDNA could significantly improve dark-adapted ERG and blue flicker response.”
BackgroundChung, D. C., & Traboulsi, E. I. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.004 · Cited by 138
AAV-mediated gene therapy for retinal disorders: from mouse to man
Buch, P. K., Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.66 · Cited by 134
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
In Vivo Gene Therapy in Young and Adult RPE65-/- Dogs Produces Long-Term Visual Improvement
Narfstrom, K. (2003) · Journal of Heredity · doi:10.1093/jhered/esg015 · Cited by 120
“Further, it was recently reported that gene therapy in three 4-month-old dogs with the same mutation resulted in visual improvement (Acland et al. 2001).”
BackgroundRPE65 Is an Iron(II)-dependent Isomerohydrolase in the Retinoid Visual Cycle
Moiseyev, G., Takahashi, Y., Chen, Y., Gentleman, S., Redmond, T. M., Crouch, R. K., & Ma, J.-X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508903200 · Cited by 119
Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 119
Munemasa, Y., & Kitaoka, Y. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00060 · Cited by 136
“Adenoviral vectors are effective in reducing functional damage in several models of ocular disease (Ali et al., 2000; Acland et al., 2001).”
BackgroundNeuroprotective Effect of Subretinal Implants in the RCS Rat
Pardue, M. T., Phillips, M. J., Yin, H., Sippy, B. D., Webb-Wood, S., Chow, A. Y., & Ball, S. L. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0515 · Cited by 117
“Despite the many technological obstacles to producing a mechanical device that interfaces with the neural retina, potential advantages to this approach include (1) the potential applicability to all forms of photoreceptor degeneration; (2) the avoidance of ethical issues related to transplantation of fetal retinal tis…”
BackgroundLentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B
Hashimoto, T., Gibbs, D., Lillo, C., Azarian, S. M., Legacki, E. L., Zhang, X., Yang, X.-J., & Williams, D. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302897 · Cited by 125
Bemelmans, A.-P., Kostic, C., Crippa, S. V., Hauswirth, W. W., Lem, J., Munier, F. L., Seeliger, M. W., Wenzel, A., & Arsenijevic, Y. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030347 · Cited by 117
“[12] revealed the clinical potential of Rpe65 gene transfer.”
BackgroundSelf-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Aguirre, G. K., Komáromy, A. M., Cideciyan, A. V., Brainard, D. H., Aleman, T. S., Roman, A. J., Avants, B. B., Gee, J. C., Korczykowski, M., Hauswirth, W. W., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040230 · Cited by 117
“Far less information is available on the details of recovery in postretinal visual pathways [10], and especially cortical visual function [1,11].”
BackgroundMethodResultInfluentialSelf-citationSlijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 135
Gene therapy: The first two decades and the current state‐of‐the‐art
Flotte, T. R. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21173 · Cited by 118
Harvey, A. R., Kamphuis, W., Eggers, R., Symons, N. A., Blits, B., Niclou, S., Boer, G. J., & Verhaagen, J. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1168 · Cited by 114
Progress and Prospects: Gene Therapy Clinical Trials (Part 1)
Alton, E. W. F. W. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303001 · Cited by 128
Banin, E., Gootwine, E., Obolensky, A., Ezra-Elia, R., Ejzenberg, A., Zelinger, L., Honig, H., Rosov, A., Yamin, E., Sharon, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.114 · Cited by 113
Self-citationGene therapy rescues cilia defects and restores olfactory function in a mammalian ciliopathy model
McIntyre, J. C., Davis, E. E., Joiner, A., Williams, C. L., Tsai, I.-C., Jenkins, P. M., McEwen, D. P., Zhang, L., Escobado, J., Thomas, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2860 · Cited by 113
Raisler, B. J., Berns, K. I., Grant, M. B., Beliaev, D., & Hauswirth, W. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122247299 · Cited by 113
Self-citationInherited retinal degenerations: therapeutic prospects
Delyfer, M., Léveillard, T., Mohand‐Saïd, S., Hicks, D., Picaud, S. A., & Sahel, J. (2004) · Biology of the Cell · doi:10.1111/j.1768-322x.2004.tb01414.x · Cited by 125
“Gene transfer has been successfully achieved in various models of RP and was shown to restore visual function in the RPE65 Briard dog (Acland et al., 2001).”
Retinoids for treatment of retinal diseases
Palczewski, K. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.03.001 · Cited by 111
Understanding hereditary diseases using the dog and human as companion model systems
Tsai, K. L., Clark, L. A., & Murphy, K. E. (2007) · Mammalian Genome · doi:10.1007/s00335-007-9037-1 · Cited by 131
“In 2001, gene therapy restored vision to dogs with severe retinal degeneration caused by a homozygous, 4-bp deletion in RPE65 (Acland et al. 2001).”
BackgroundTaking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Self-citationAnimal Models of Retinal Disease
Fletcher, E. L., Jobling, A. I., Vessey, K. A., Luu, C. D., Guymer, R. H., & Baird, P. N. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00006-6 · Cited by 119
“A crucial step in the development of gene therapy for LCAwas the successful treatment of Briard sheep dogs in 2001.(18) Recombinant canine RPE65 was injected either intravitreally or subretinally at approximately 4 months of age and visual function tested 3 months later.”
BackgroundMethodAdeno-associated virus vectors: potential applications for cancer gene therapy
Li, C., Bowles, D. E., Dyke, T. V., & Samulski, R. J. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700876 · Cited by 117
Retinitis Pigmentosa and Allied Disorders
Gregory-Evans, K., Pennesi, M. E., & Weleber, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00040-0 · Cited by 122
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Self-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109
“Viral gene therapy has been remarkably successful in treating some types of ocular diseases, the most notable example of which to date being the AAV-mediated long-term rescue of vision in Briard dogs harboring a mutation in RPE65 [1,2].”
BackgroundCell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases
Jones, M. K., Lü, B., Girman, S., & Wang, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.004 · Cited by 125
“Using animal models of LCA, subretinal injections of adeno-associated virus (AAV) mediated RPE65 gene delivery was able to restore vision (Acland et al., 2005, 2001; Bennicelli et al., 2008).”
MethodBestrophinopathy: An RPE-photoreceptor interface disease
Guziewicz, K. E., Sinha, D., Gómez, N. M., Zorych, K., Dutrow, E. V., Dhingra, A., Mullins, R. F., Stone, E. M., Gamm, D. M., Boesze-Battaglia, K., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.005 · Cited by 108
“…A uthor M anuscript A uthor M anuscript A uthor M anuscript inherited retinal disorders in man have proved crucial in the investigation of disease mechanisms and development of new therapeutic strategies (Acland et al., 2001; Komaromy et al., 2010; Beltran et al., 2012; Downs et al., 2016).”
Self-citationA Digital Atlas of the Dog Brain
Datta, R., Lee, J., Duda, J., Avants, B., Vite, C. H., Tseng, B., Gee, J. C., Aguirre, G. K., & Aguirre, G. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052140 · Cited by 115
“[9–11]).”
Self-citationZentilin, L., Marcello, A., & Giacca, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12279-12287.2001 · Cited by 101
“Despite the increasing popularity of recombinant AAV (rAAV) vectors and the successful applications of AAV-mediated gene transfer in preclinical and clinical studies (3, 14, 31), the molecular mechanisms responsible for efficient rAAV transduction are still poorly defined.”
BackgroundLotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.